PUMA BIOTECHNOLOGY INC (PBYI) is a publicly traded Healthcare sector company. As of May 21, 2026, PBYI trades at $7.00 with a market cap of $346.63M and a P/E ratio of 13.95. PBYI moved +2.50% today. Year to date, PBYI is +17.68%; over the trailing twelve months it is +92.56%. Its 52-week range spans $2.32 to $7.90. Analyst consensus is neutral with an average price target of $5.00. Rallies surfaces PBYI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Puma Biotechnology Q4 Revenue Hits $75.5M on $59.9M NERLYNX Sales: Puma reported Q4 2025 total revenue of $75.5 million, driven by NERLYNX net sales of $59.9 million (up $8.0 million sequentially) and royalty revenue of $15.6 million. The company sold 3,298 NERLYNX bottles (up 349 sequentially), saw field call activity rise 23% year-over-year, and expects sequential recovery.
| Metric | Value |
|---|---|
| Price | $7.00 |
| Market Cap | $346.63M |
| P/E Ratio | 13.95 |
| EPS | $0.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.90 |
| 52-Week Low | $2.32 |
| Volume | 33 |
| Avg Volume | 0 |
| Revenue (TTM) | $227.18M |
| Net Income | $24.38M |
| Gross Margin | 74.46% |
1 analysts cover PBYI: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $5.00.